TCD Followed by autoSCT for Newly Diagnosed MM Patients
Recruitment status was Recruiting
Multiple Myeloma is a incurable disease. Thalidomide in combination with other agents are currently in trials for the newly diagnosed patients, we designed treatment of TCD, followed by high dose chemotherapy with autologous stem cell transplantation and TD maintenance therapy for the patients with newly diagnosed multiple myeloma.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Induction Therapy With TCD Regimen (Thalidomide, Cyclophosphamide, Dexamethasone) Followed by Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients|
- Response rate of TCD induction Therapy
- Progression free survival and Overall survival of TCD, followed by high dose chemotherapy and autoPBSCT and TD maintenance
- To evaluate toxicities of TCD, followed by high dose chemotherapy and autoPBSCT and TD maintenance.
|Study Start Date:||June 2006|
|Estimated Study Completion Date:||June 2008|
Phase II clinical trial for the patients with newly diagnosed. TCD (thalidomide, cyclophosphamide and dexamethasone) will be applied for the patients as an induction chemotherapy, followed by high dose chemotherpy and autologous stem cell transplantation. Afterthen, they will receive TD (thalidomide and dexamethasone) maintenance therapy for one year.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00349115
|Contact: Je-Jung Lee, MD, PhDfirstname.lastname@example.org|
|Contact: Yeo-Kyeoung Kim, MD, PhDemail@example.com|
|Korea, Republic of|
|Hwsun-eup, Hwasun-gun, Jeollanam-do, Korea, Republic of, 519-809|
|Contact: Yeo-Kyeoung Kim, MD, PhD 82-61-379-7639 firstname.lastname@example.org|
|Principal Investigator: Je-Jung Lee, MD, PhD|
|Principal Investigator:||Je-Jung Lee, MD, PhD||Chonnam National University Hospital|